The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, which included patients with 3-vessel or left main coronary artery lesions, showed that myocardial revascularization surgery (MRS) turned out to be superior to angioplasty with drug-eluting stents (DES), mainly due to differences in acute myocardial infarction and repeat revascularization. Up to this work, patient sensations (which can be...
Transcatheter valve replacement in the bicuspid valve is increasingly performed, but challenges remain
As experience increases, transcatheter aortic valve replacement (TAVR) has expanded to different populations and anatomies. This study sought to compare technical and clinical outcomes in patients with bicuspid versus tricuspid aortic stenosis from the Bicuspid AS TAVR Multicenter Registry. Outcomes of 561 patients with bicuspid valves and 4546 patients with tricuspid valves were compared. Propensity score matching was used...
TAVR presents less post-procedural MI than surgical aortic valve replacement
Courtesy of Dr. Carlos Fava. Surgical aortic valve replacement (SAVR) continues to be elective, but the presence of post-procedural acute myocardial infarction (AMI) has been associated to bad evolution. Despite the proven benefits of TAVR for high risk patients and the progress shown by patients of intermediate risk, the incidence of post implantation MI has...
Bicuspid Aortic Valve Stenosis Still Challenging for TAVR
Courtesy of Dr. Carlos Fava One of the present challenges of TAVR is bicuspid aortic valve stenosis (AS), since it presents a different distribution and structure, associated to greater and more irregular calcification. There are only small series of devices and their use is still controversial. The study analyzed 561 patients with severe bicuspid...
TAVR: Transcarotid Access as a Valid Alternative
Courtesy of Dr. Carlos Fava. Transfemoral access is the first choice for transcatheter aortic valve replacement (TAVR). However, this approach is not feasible for a progressively larger number of patients, which establishes the need to search for alternative accesses. Between 2009 and 2014, this study enrolled 174 patients who underwent TAVR and were unsuitable for transfemoral...
New TAVR Devices: Better Results in Bicuspids
Courtesy of del Dr. Carlos Fava. The bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group. 301 patients presenting bicuspid aortic valve undergoing transcatheter aortic...
One year outcomes of the new repositionable and retrievable valve
Original Title: 1-Year Outcomes with the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients with Severe Aortic Stenosis Results of the REPRISE II Study. Reference: Ian T. Meredith et al. J Am Coll Cardiol Intv. 2016;9(4):376-384. This analysis represents the first report at one year of 120 patients enrolled...
REPRISE II: results obtained with the new valve according to VARC criteria
The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical risk. The study included 60 patients who received the device and were followed during 30 days. Mortality from all causes was 1.7% and the incidence of stroke was 8.6%, with half...
Results of the new repositionable and retrievable percutaneous valve system
Original title: Transcatheter Aortic Valve Replacement for Severe Symptomatic Aortic Stenosis Using a Repositionable Valve System. 30-Day Primary Endpoint Results From the REPRISE II Study. Reference: Ian T. Meredith AM et al. J Am Coll Cardiol 2014;64:1339–48. Transcatheter aortic valve replacement (TAVR) showed results comparable to those of surgery in patients at high surgical risk, but complications can...